Season 2| China: Brad Loncar on Investment Risk and Innovation Drivers in Chinese Biotech

Season 2| China: Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy

Hong Tang Biography Dr. Hong Tang [https://cn.linkedin.com/in/hong-tang-md-facp-b203823b] is Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified internal medicine physician with more than 15 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH. OnQuality Pharmaceuticals is designing targeted cancer supportive care treatments aimed at preventing and treating the intolerable side effects caused by specific cancer drugs. Their mission is to make fighting cancer easier by alleviating the side effects of anti-cancer therapy, so the patients can continue cancer treatment and live with a better quality of life. OnQuality is based in Seattle and Shanghai. She received her medical degree in Traditional Chinese Medicine in Hefei, China, pursued her graduate study in Western medicine in Guangzhou, China, and at the University of Texas in San Antonio. She is also board certified in internal medicine and practiced as an internist in Indiana for almost 7 years. In this episode of Behind Biotech, we spoke with Hong about: 1. Starting her career in Traditional Chinese Medicine, and how this education on holistic patient care influenced her career path 2. The need for more targeted cancer supportive therapy, such as IL-6 inhibitors for CAR-T 3. OnQuality’s current pipeline in oncodermatology and oncogastroenterology

Season 2 | China: George Chen on Building a "In China, for Global" Biotech

George Chen Biography George Chen, MD MBA, [https://cn.linkedin.com/in/george-chen-md-mba-4a85a030] is an oncologist by training with a successful track record in the world of global pharmaceutical companies.  Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, BeiGene, and Astra Zeneca.  At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs.  His medical degree is from the Shanghai Medical College of Fudan University and his MBA is from the Wharton School of Business at the University of Pennsylvania. D3 Bio D3 Bio, Inc [https://www.d3bio.com/]is an “in China, for global” biotech company aiming to become a world-class biotherapeutic company to develop and register the First/best-in-class medicines for cancer and autoimmune disease patients in large unmet medical needs through a continuously progressing cycle of using the insight of Development to guide Discovery and back to Development process. The company has launched 6 pre-clinical portfolio projects with first and best in class potential and recently received IND clearance from the FDA to initiate Phase 1 trial for D3S-001 [https://www.d3bio.com/press-releases/d3-bio-received-ind-clearance-from-fda-to-initiate-phase-i-clinical-trial-in-us-for-d3s-001]. D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund. In this episode of Behind Biotech, we spoke with George about: 1. Training as an oncologist in China in the 80s and his motivation to come to the US to learn about immunotherapy 2. His experience of building the foundation of BeiGene as the company’s first Chief Medical Officer 3. The success story of and lessons learned from developing Tagrisso, an EGFR-TKI for NSCLC, at Astrazeneca China 4. D3 Bio’s plans after launching with a $200M Series A-the second largest Series A in 2020 of any biotech company

Season 2| China: Bing Yuan on Global Outlicensing of Chinese Biotech

Dr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals. As a senior executive from the beginning, he helped to build the company from scratch to successful IPO and a fully integrated biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D project management and commercial organization. He successfully reached close to 10 strategic partnerships with Pfizer, Bayer, Blueprint, Agios, EQRx, etc. Before joining CStone in November 2016, he spent 22 years in the USA. He was Executive Director and Global Lead of Oncology BD&L at Merck (MSD), Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, Global Oncology Marketing Lead at Eisai, and Product Manager at Thermo-Fisher. He successfully led or contributed to over 40 M&A, licensing and Keytruda clinical collaboration deals. As a core member of the global project team (GPT), he played a key role in designing development strategy for 5 oncology drugs. He used to lead Glivec and Afinitor brand life cycle strategy, and participated in global launch of Zykadia in ALK+ lung cancer. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University. In this episode of Behind Biotech with Bing, we discussed: Bing's professional journey from China to the US and back to China Catalysts behind the striking growth of the Chinese Biotech industry starting in 2015 Pioneering new models of global outlicensing of Chinese Biotech with OnCusp Therapeutics

Season 2| China: Shawn Xiang on Building China's Rare Disease Ecosystem

Shawn Xiang Biography Dr. Xiang is the CEO of Rarestone Group [http://www.rarestonegroup.com/en/], a company building the first rare disease ecosystem in China. Dr. Xiang has more than 15 years of leadership experience in pharmaceutical and medical device industries. Prior to RareStone, Shawn was the General Manager of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led his team and successfully launched FreeStyle Libre in China, Korea and Southeast Asia markets and achieved hyper-growth consecutively over the years. Shawn also led his team to build an ecosystem for patients living with Type 1 Diabetes, through strong collaboration with patient organizations, governments and industry partners. Prior to Abbott, Shawn served as the Franchise Head of Bone Disease and Respiratory Disease at Novartis China.  He also served as the Director of Global Pharma Strategy at Novartis Global in Switzerland.  Earlier in his career, Shawn was an Engagement Manager at McKinsey & Co. in the USA. Dr. Xiang holds a PhD degree from Yale University and a BS degree from Peking University. On this episode of Behind Biotech, we discussed with Shawn: 1. Common misconceptions about rare disease in China 2. Recent catalysts which catapulted rare disease development in China 3. Rarestone’s unique model which combines a traditional biotech with a digital patient ecosystem

Season 2| China: Brad Loncar on Investment Risk and Innovation Drivers in Chinese Biotech

Brad Loncar Biography Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. He’s also the co-host of Biotech Clubhouse, which recaps the week’s biotech news every Sunday at 4pm EST. On this episode we discussed with Brad: 1. How he first became interested in China biopharma and his advice for getting ‘smart’ on the industry as a foreign investor. 2. Key players in the China biopharma ecosystem, including investors as well as founder and company profiles 3. How investors should think about regulatory and geopolitical risk when it comes to investing in China biotech